NextCure (NASDAQ:NXTC) Reaches New 52-Week High on Analyst Upgrade

NextCure Inc (NASDAQ:NXTC) shares reached a new 52-week high on Tuesday after Morgan Stanley raised their price target on the stock from $25.00 to $33.00. Morgan Stanley currently has an overweight rating on the stock. NextCure traded as high as $27.73 and last traded at $27.73, with a volume of 2551 shares. The stock had previously closed at $24.24.

NXTC has been the topic of a number of other research reports. Bank of America initiated coverage on shares of NextCure in a research note on Tuesday, July 9th. They set a “buy” rating and a $25.00 price target on the stock. Piper Jaffray Companies initiated coverage on shares of NextCure in a research note on Monday, June 3rd. They set an “overweight” rating and a $26.00 price target on the stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp bought a new stake in NextCure during the 2nd quarter worth approximately $337,000. Charles Schwab Investment Management Inc. acquired a new position in NextCure during the 2nd quarter worth approximately $386,000. Yale University acquired a new position in NextCure during the 2nd quarter worth approximately $1,865,000. Fosun International Ltd acquired a new position in NextCure during the 2nd quarter worth approximately $2,247,000. Finally, Matthews International Capital Management LLC acquired a new position in NextCure during the 2nd quarter worth approximately $6,741,000. 2.06% of the stock is owned by institutional investors and hedge funds.



The stock has a 50-day moving average of $18.66.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.15). The business had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. As a group, equities analysts anticipate that NextCure Inc will post -2.14 EPS for the current year.

NextCure Company Profile (NASDAQ:NXTC)

There is no company description available for NextCure Inc

Recommended Story: Cryptocurrencies

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.